(Q38956651)

English

Docetaxel rechallenge in metastatic castration-resistant prostate cancer: any place in the modern treatment scenario? An intention to treat evaluation

scientific article published on 5 October 2015

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Docetaxel rechallenge in metastatic castration-resistant prostate cancer: any place in the modern treatment scenario? An intention to treat evaluation (English)

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

1 reference

based on heuristic

inferred from title

Amelia Altavilla

object named as

Amelia Altavilla

12

0 references

author name string

Sergio Bracarda

1

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Claudia Caserta

2

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Luca Galli

3

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Paolo Carlini

4

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Ilaria Pastina

5

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Michele Sisani

6

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Simona Scali

7

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Alketa Hamzaj

8

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Lisa Derosa

9

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Alessandra Felici

10

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Marta Rossi

11

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Aldo Chioni

13

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Verena De Angelis

14

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

language of work or name

0 references

publication date

5 October 2015

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Future Oncology

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

11

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

22

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

3083-3090

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.217

21 January 2018

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.217

21 January 2018

Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous treatment strategies.

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.217

21 January 2018

Interrupted versus continuous chemotherapy in patients with metastatic breast cancer. The Piedmont Oncology Association

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.217

21 January 2018

Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: a multicentre randomised trial

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.217

21 January 2018

Intermittent chemotherapy in metastatic androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.217

21 January 2018

Intermittent chemotherapy in patients with metastatic androgen-independent prostate cancer: results from ASCENT, a double-blinded, randomized comparison of high-dose calcitriol plus docetaxel with placebo plus docetaxel

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.217

21 January 2018

Intermittent docetaxel therapy with estramustine for hormone-refractory prostate cancer in Japanese patients

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.217

21 January 2018

Combination of hemoglobin, alkaline phosphatase, and age predicts optimal docetaxel regimen for patients with castration-resistant prostate cancer.

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.217

21 January 2018

Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer.

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.217

21 January 2018

Clinical implications for a treatment algorithm and differential indication to hormone therapy and chemotherapy options in metastatic castrate-resistant prostate cancer: a personal view.

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.217

21 January 2018

Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019).

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.217

21 January 2018

AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.217

21 January 2018

Identifiers

10.2217/FON.15.217

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38956651&oldid=1799099792"